Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001
NCT ID: NCT03004495
Last Updated: 2016-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2016-01-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CHF5259 and CHF6001
(T): CHF6001 + CHF5259 b.i.d. for 14 days
CHF5259 and CHF6001
b.i.d. for 14 days
CHF5259 + placebo
(R1): CHF5259 25µg b.i.d. for 14 days
CHF5259 + placebo
b.i.d. for 14 days
Placebo
b.i.d. for 14 days
CHF6001 + placebo
(R2): CHF6001 b.i.d. for 14 days
CHF6001 + placebo
b.i.d. for 14 days
Placebo
b.i.d. for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CHF5259 and CHF6001
b.i.d. for 14 days
CHF5259 + placebo
b.i.d. for 14 days
CHF6001 + placebo
b.i.d. for 14 days
Placebo
b.i.d. for 14 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to understand the study procedures and the involved risks, ability to be trained to use the device correctly
* Non smokers or ex-smokers are eligible.
* Good physical and mental status, determined on the basis of the medical history and a general clinical examination;
* Vital signs checked at screening visit and Day -1: Subjects aged 18-45years: Diastolic BP 40-90, Systolic BP 90-140; Subjects aged 46-55 years: Diastolic BP 40-90, Systolic BP 90-150
* 12-lead digitised Electrocardiogram (12-lead ECG) considered as normal (40≤Heart rate≤110bpm,120 ms ≤ PR ≤ 210 ms, QRS ≤ 120 ms, QTcF ≤ 450 ms for males and ≤ 470ms for females) checked at screening;
* Lung function measurements within normal limits: FEV1 \> 80% of predicted normal value (according to the Global Lung Function Initiative, ERS Task Force Lung Function Reference Values (1,2) ) and FEV1/FVC ratio \> 0.70;
* Male subjects: they and/or their partner of childbearing potential must be willing to use a double contraceptive methods;
* Female subject of non-childbearing potential (WONCBP) Female subjects of childbearing potential (WOCBP) fulfilling one of the following criteria: WOCBP with fertile male partners: they and/or their partner of childbearing potential must be willing to use a double contraceptive methods including one highly effective birth control method and one acceptable birth control method, from the signature of the informed consent and until three months following the last study drug intake; WOCBP with non-fertile male partners: contraception is not required in this case.
Exclusion Criteria
* Blood donation (equal or more than 450 ml) or blood loss less than 12 weeks before inhalation of the study medication;
* Positive HIV1 or HIV2 serology; Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C (positive HB surface antigen (HBsAg),HB core antibody ( anti HBc), HC antibody);
* History of substance abuse or drug abuse within 12 months prior to screening visit;
* Clinically significant abnormal 24-h Holter ECG at screening as defined in the Holter interpretative guidelines (Appendix V);
* Any clinically relevant abnormal laboratory value at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the result of the study according to the Investigator's judgment;
* Clinically significant and uncontrolled respiratory, cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, respiratory or psychiatric disorder that may interfere with successful completion of this protocol;
* Subjects with medical diagnosis asthma including childhood asthma;
* Subjects known to have intolerance/ hypersensitivity to M3 Antagonists, or any of the excipients contained in any of the formulations used in the trial;
* Any drug treatment, including prescribed or OTC medicines as well as vitamins, homeopathic remedies etc, taken in the 14 days (3 months for any biologic drugs, enzyme-inducing or enzyme-inhibiting drugs e.g., glucocorticoids, phenobarbital, isoniazid) before the screening visit, with the exception of occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days for mild non-excluding conditions), hormonal contraceptives and hormonal replacement treatment for post-menopausal women;
* Treatment within the previous 3 months before the screening visit with any drug known to have a well defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole);
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Quintiles, Inc.
INDUSTRY
Chiesi Farmaceutici S.p.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronnie Beboso, MD
Role: PRINCIPAL_INVESTIGATOR
Quintiles, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Quintiles CPU
London, UK, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCD-06302AA1-02
Identifier Type: -
Identifier Source: org_study_id